Liposomes surface conjugated with human hemoglobin target delivery to macrophages

Biotechnology and Bioengineering

Volumn 109, Issue 3, 2012, Pages 823-829

  Zhang, Ning ^a,b   Palmer, Andre F ^a  

^a Ohio State University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

CD 163 receptor; Hb liposome; Hemoglobin; Liposome; Macrophage; Targeted drug delivery

Indexed keywords

CALCEIN; CD-163 RECEPTOR; DELIVERY SYSTEMS; DRUG DELIVERY SYSTEM; FLUORESCENT DYES; HB-LIPOSOME; NOVEL STRATEGIES; RECEPTOR-MEDIATED ENDOCYTOSIS; SCAVENGING ACTIVITIES; TARGET DELIVERY; TARGETED DRUG DELIVERY; THERAPEUTIC MOLECULES; TISSUE TYPES;

DRUG DELIVERY; HEMOGLOBIN; LIPOSOMES; MOLECULAR BIOLOGY; MOLECULES; PHOSPHOLIPIDS; TISSUE;

MACROPHAGES;

CALCEIN; CD163 ANTIGEN; HAPTOGLOBIN; HEMOGLOBIN; LIPOSOME;

ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; ENDOCYTOSIS; FLOW RATE; HUMAN; LIGHT SCATTERING; MACROPHAGE; PROTEIN BINDING; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL TRANSPORT; DRUG CARRIERS; ENDOCYTOSIS; FLUORESCEINS; FLUORESCENT DYES; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; LIPOSOMES; MACROPHAGES; PROTEIN BINDING; RECEPTORS, CELL SURFACE; STAINING AND LABELING;

EID: 84855921306     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24340     Document Type: Article

References (26)

1. Brookes S, Biessels P, Ng NF, Woods C, Bell DN, Adamson G. 2006. Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted drug delivery. Bioconjug Chem 17(2): 530-537.
2. Bunn HF, Esham WT, Bull RW. 1969. The renal handling of hemoglobin. I. Glomerular filtration. J Exp Med 129(5): 909-923.
3. Cao Z, Tong R, Mishra A, Xu W, Wong GC, Cheng J, Lu Y. 2009. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl 48(35): 6494-6498.
4. Danoff EJ, Wang X, Tung SH, Sinkov NA, Kemme AM, Raghavan SR, English DS. 2007. Surfactant vesicles for high-efficiency capture and separation of charged organic solutes. Langmuir 23(17): 8965-8971.
5. Elmer J, Buehler PW, Jia YP, Wood F, Harris DR, Alayash AI, Palmer AF. 2010. Functional comparison of hemoglobin purified by different methods and their biophysical implications. Biotechnol Bioeng 106(1): 76-85.
6. GhoshMoulick R, Bhattacharya J, Roy S, Basak S, Dasgupta AK. 2007. Compensatory secondary structure alterations in protein glycation. Biochim Biophys Acta 1774(2): 233-242.
7. Honma Y. 2001. A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors. Leuk Lymphoma 42(5): 953-962.
8. Hu T, Li D, Manjula BN, Acharya SA. 2008. Autoxidation of the site-specifically PEGylated hemoglobins: Role of the PEG chains and the sites of PEGylation in the autoxidation. Biochemistry 47(41): 10981-10990.
9. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. 2000. Macrophages in rheumatoid arthritis. Arthritis Res 2(3): 189-202.
10. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. 2001. Identification of the haemoglobin scavenger receptor. Nature 409(6817): 198-201.
11. Manjula BN, Tsai A, Upadhya R, Perumalsamy K, Smith PK, Malavalli A, Vandegriff K, Winslow RM, Intaglietta M, Prabhakaran M, et al. 2003. Site-specific PEGylation of hemoglobin at Cys-93(beta): Correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug Chem 14(2): 464-472.
12. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, et al. 2007. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447(7148): 1116-1120.
13. Palmer AF, Sun G, Harris DR. 2009. Tangential flow filtration of hemoglobin. Biotechnol Prog 25(1): 189-199.
14. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. 2006. Immunotoxin therapy of cancer. Nat Rev Cancer 6(7): 559-565.
15. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12): 751-760.
16. Perrie Y, Barralet JE, McNeil S, Vangala A. 2004. Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route. Int J Pharm 284(1-2): 31-41.
17. Samad A, Sultana Y, Aqil M. 2007. Liposomal drug delivery systems: An update review. Curr Drug Deliv 4(4): 297-305.
18. Shen Y. 2008. Advances in the development of siRNA-based therapeutics for cancer. IDrugs 11(8): 572-578.
19. Soni V, Kohli DV, Jain SK. 2005. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J Drug Target 13(4): 245-250.
20. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y. 2001. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release 75(1-2): 83-91.
21. Torchilin V. 2008. Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5(9): 1003-1025.
22. Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM. 2003. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion 43(4): 509-516.
23. Vandegriff KD, Malavalli A, Minn C, Jiang E, Lohman J, Young MA, Samaja M, Winslow RM. 2006. Oxidation and haem loss kinetics of poly(ethylene glycol)-conjugated haemoglobin (MP4): Dissociation between in vitro and in vivo oxidation rates. Biochem J 399(3): 463-471.
24. Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM, Perrie Y. 2007. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 119(1): 102-110.
25. Wang Y, Wang X, Zhang Y, Yang S, Wang J, Zhang X, Zhang Q. 2009. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. J Drug Target 17(6): 459-467.
26. Zhang N, Palmer AF. 2011. Development of a dichloroacetic acid-hemoglobin conjugate as a potential targeted anti-cancer therapeutic. Biotechnol Bioeng 108(6): 1413-1420.